Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-based optimization of MurF inhibitors.

Geoffrey F Stamper1, Kenton L Longenecker, Elizabeth H Fry

  • 1Global Pharmaceutical Research & Development, Department of Structural Biology, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA. geoffrey.stamper@abbott.com

Chemical Biology & Drug Design
|February 24, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of Fosigotifator, a Potent eIF2B Activator with Desired Properties for Human Studies.

Journal of medicinal chemistry·2026
Same author

Recent trends in pharmaceutical freeze-drying and control strategies observed in human drug applications and manufacturing inspections.

AAPS open·2026
Same author

Urine Amphetamine Screening and Suicidality: A 5-Year Retrospective Analysis of Emergency Department Patients.

The Journal of emergency medicine·2025
Same author

Discovery of Orally Efficacious Bridged Piperazines as smTNF Modulators.

Journal of medicinal chemistry·2025
Same author

Promethazine: A Review of Therapeutic Uses and Toxicity.

The Journal of emergency medicine·2025
Same author

Response to comment on "Acute adverse effects of F(ab')₂AV and FabAV use for rattlesnake envenomation".

The American journal of emergency medicine·2024

Researchers developed potent, low-nanomolar inhibitors targeting the essential bacterial enzyme MurF (D-Ala-D-Ala adding enzyme). This advancement offers a promising new avenue for antibacterial drug discovery against Streptococcus pneumoniae.

Area of Science:

  • Microbiology
  • Medicinal Chemistry
  • Structural Biology

Background:

  • The D-Ala-D-Ala adding enzyme (MurF) from Streptococcus pneumoniae is essential for bacterial cell wall synthesis.
  • MurF is a validated antibacterial target due to its essential, non-redundant function and bacterial specificity.
  • Previous work identified a new class of MurF inhibitors and determined their cocrystal structure.

Purpose of the Study:

  • To initiate a medicinal chemistry program to enhance the potency of existing MurF inhibitors.
  • To leverage structural information for rational drug design and optimization.

Main Methods:

  • A multidisciplinary approach combining medicinal chemistry and structural biology.
  • Rapid generation and analysis of cocrystal structures of MurF with inhibitors.

Related Experiment Videos

  • Structure-guided design and iterative optimization of inhibitor compounds.

    • Main Results:

    • Successful optimization of MurF inhibitors.
    • Discovery of novel inhibitors with low-nanomolar potency.
    • Detailed crystallographic insights guiding the optimization process.

    Conclusions:

    • The multidisciplinary, structure-guided approach is effective for rapid optimization of antibacterial inhibitors.
    • Low-nanomolar inhibitors of MurF were discovered, representing significant progress in antibacterial drug development.
    • These findings provide a strong foundation for further development of MurF-targeted therapeutics.